文献速递系统性红斑狼疮其他结缔组织病

古塞奇尤单抗治疗活动性狼疮肾炎的疗效与安全性:一项2期随机安慰剂对照研究结果

Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项2期多中心随机双盲安慰剂对照研究因入组困难提前终止,仅33例活动性狼疮肾炎患者随机接受古塞奇尤单抗或安慰剂。第24周时,安慰剂组56.3%(9/16)和古塞奇尤单抗组35.3%(6/17)达到主要终点,次要终点未见明显差异。古塞奇尤单抗联合背景治疗在小样本中未显示优于安慰剂的蛋白尿下降效果,安全性特征与已知一致。

要点

  • 研究因COVID-19疫情及乌克兰/俄罗斯危机入组困难提前终止,仅33例随机。
  • 第24周主要终点达标率:安慰剂组56.3%(9/16) vs 古塞奇尤单抗组35.3%(6/17)。
  • 次要终点未见明显差异;截至研究结束,两组不良事件发生率分别为75%和71%。

核心结论

  • 在活动性狼疮肾炎小样本中,古塞奇尤单抗联合背景治疗相比安慰剂联合背景治疗未显示更优的蛋白尿下降效果。
  • 安全性结果与古塞奇尤单抗已知安全性特征一致。

研究设计与样本

  • 2期多中心随机双盲安慰剂对照研究,计划样本量60例,实际随机33例(安慰剂组16例,古塞奇尤单抗组17例)。
  • 纳入18-75岁活动性狼疮肾炎患者(肾活检III-IV型增殖性肾炎且尿蛋白/肌酐比≥1 mg/mg,尽管接受标准治疗)。
  • 随机1:1接受静脉输注古塞奇尤单抗400 mg或安慰剂(第0、4、8周),随后皮下注射古塞奇尤单抗200 mg或安慰剂(第12周起每4周一次至第48周),均联合背景治疗。

主要发现

  • 第24周主要终点(蛋白尿较基线下降≥50%)达标率:安慰剂组56.3%(9/16) vs 古塞奇尤单抗组35.3%(6/17)。
  • 第24周次要终点(完全肾脏缓解、激素持续减量至≤10 mg/天泼尼松等效、UPCR<0.5 mg/mg、UPCR<0.75 mg/mg、至完全肾脏缓解时间、至治疗失败时间)未见明显差异。
  • 截至研究结束,安慰剂组75%和古塞奇尤单抗组71%的患者报告至少1例不良事件,大多为轻至中度。

关键数值与推荐

  • 主要终点:第24周蛋白尿较基线下降≥50%。
  • 主要次要终点(第24周):完全肾脏缓解、第16-24周激素持续减量至≤10 mg/天泼尼松等效、UPCR<0.5 mg/mg、UPCR<0.75 mg/mg、至完全肾脏缓解时间、至治疗失败时间。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因COVID-19疫情及乌克兰/俄罗斯危机入组困难而提前终止,仅33例随机。
  • 作者结论称该小样本队列中古塞奇尤单抗未显示优于安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Evaluate the efficacy and safety of guselkumab, an IL-23p19-subunit inhibitor, in a phase 2, multicentre, randomized, double-blind, placebo-controlled study of patients with active LN. METHODS: Adults (18-75 years) with active LN [Class III-IV proliferative nephritis (kidney biopsy) and urine protein-to-creatinine ratio (UPCR) of ≥1 mg/mg despite standard-of-care therapy] were randomized (1:1; planned sample = 60) to receive i.v. infusions of guselkumab 400 mg or placebo at weeks 0, 4 and 8, then s.c. injections (guselkumab 200 mg or placebo) at week 12 and every 4 weeks through week 48 in addition to their background therapy. The primary endpoint was achievement of ≥50% decrease in proteinuria from baseline at week 24. Major secondary endpoints (week 24) were achievement of complete renal response (CRR), sustained reduction in steroid dose (≤10 mg/day prednisone/equivalent) from weeks 16-24, UPCR <0.5 mg/mg; <0.75 mg/mg, time to achieving CRR, and time to treatment failure. Safety was assessed through the end of the study. RESULTS: Following enrolment challenges (COVID-19 pandemic; Ukraine/Russia crisis), the sponsor terminated the study early; 33 participants were randomized (placebo, n = 16; guselkumab, n = 17). At week 24, 56.3% (9/16) in the placebo group and 35.3% (6/17) in the guselkumab group achieved the primary endpoint. No apparent differences were observed in the secondary endpoints. Through end-of-study, 75% of placebo patients and 71% of guselkumab patients reported ≥1 adverse event; most were of mild-to-moderate severity. CONCLUSION: Guselkumab+background therapy did not demonstrate superior reduction in proteinuria vs placebo+background therapy in this small cohort of patients with active LN. Safety results were consistent with the known safety profile of guselkumab. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04376827.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Anders HJ, Chan TM, Sanchez-Guerrero J, et al. Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford). 2025. PMID: 39673415. doi:10.1093/rheumatology/keae647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。